Comparative Pharmacology
Head-to-head clinical analysis: ALPROSTADIL versus MISOPROSTOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPROSTADIL versus MISOPROSTOL.
ALPROSTADIL vs MISOPROSTOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alprostadil is a synthetic prostaglandin E1 (PGE1) that causes vasodilation by binding to prostanoid EP receptors, increasing intracellular cAMP, and relaxing smooth muscle. It also inhibits platelet aggregation.
Misoprostol is a synthetic prostaglandin E1 analog that induces uterine contractions and cervical ripening by binding to prostaglandin receptors, leading to increased intracellular calcium and myometrial contraction. It also inhibits gastric acid secretion by reducing parietal cell activity and protecting gastric mucosa via increased bicarbonate and mucus production.
Initial: 20-40 mcg IV bolus over 1-2 seconds; then 30-70 mcg/min continuous IV infusion for erectile dysfunction via intracavernosal injection: 2.5-10 mcg; for patent ductus arteriosus: 0.05-0.1 mcg/kg/min continuous IV infusion.
200 mcg orally four times daily (with meals and at bedtime) for prevention of NSAID-induced gastric ulcers; 800 mcg sublingually every 4 hours for up to 3 doses for labor induction; 25 mcg orally single dose for cervical ripening.
None Documented
None Documented
Clinical Note
moderateAlprostadil + Limaprost
"Alprostadil may increase the antiplatelet activities of Limaprost."
Clinical Note
moderateAlprostadil + Epoprostenol
"Alprostadil may increase the antiplatelet activities of Epoprostenol."
Clinical Note
moderateTiaprofenic acid + Alprostadil
"The therapeutic efficacy of Alprostadil can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Alprostadil
5-10 minutes; rapidly metabolized in the lungs, clinical effect lasts longer due to continuous infusion.
2-3 hours for misoprostol acid (active metabolite); clinically, a short duration requires multiple daily dosing. In patients with renal impairment, half-life may be prolonged but not significantly clinically.
Primarily via urine (90%) as metabolites; 10% unchanged; minimal fecal excretion.
Primarily renal excretion of metabolites; ~80-90% of a radiolabeled dose is excreted in urine within 24 hours, with the remainder in feces. Misoprostol acid (active metabolite) undergoes further beta-oxidation and reduction; <1% excreted unchanged.
Category C
Category D/X
Prostaglandin Analog
Prostaglandin Analog
"The therapeutic efficacy of Alprostadil can be decreased when used in combination with Carprofen."